Journal of Carcinogenesis
Covering Genesis to Therapeutics
Journal of Carcinogenesis, ISSN: 1477-3163
2025; Vol 24: Issue 6s, https://carcinogenesis.com/

Genetic Insights: The Power of Pharmacogenomics in Shaping Personalized Treatment Strategies

Surya Nath Pandey[1], Mithul V Mammen[2], Upendra Kumar[2], Abhishek Anand[2], Amit Kumar[3], Abhishek Suma[3], Tanu shree Vyas[3]

[1]Department of Pharmacology, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad 244001, Uttar Pradesh, India-244001

[2]Department of Pharmacy Practice, Teerthanker Mahaveer College of Pharmacy, Teerthanker Mahaveer University, Moradabad, Uttar Pradesh, India -244001

[3]Shri Venkateshwara School of Pharmacy, Shri Venkateshwara University, Rajabpur, Gajraula, Amroha, Uttar Pradesh, India

Corresponding author:

Name & Address of Corresponding – Amit Kumar*

E-mail ID:amittph1812017@gmail.com

Address: Department Of Pharmacology, Shri Venkateshwara school of Pharmacy, Shri Venkateshwara University, Rajabpur, Gajraula, Amroha, Uttar Pradesh, India

ABSTRACT

Pharmacogenomics, the intersection of pharmacology and genomics, investigates how genetic variations influence individual responses to medications, offering the potential for personalized treatment strategies. This field enables tailored drug selection and dosing to enhance efficacy and minimize adverse drug reactions (ADRs), which are a significant public health concern due to their impact on morbidity, mortality, and healthcare costs. Historical milestones, from Pythagoras's observations in 510 BC to the sequencing of the human genome in 2000, have shaped pharmacogenomics, with key discoveries like the CYP2D6 gene's polymorphisms driving advancements. Genetic polymorphisms in drug-metabolizing enzymes, such as cytochrome P450, account for 20%–95% of variability in drug response, impacting pharmacokinetics and therapeutic outcomes. Clinical applications span specialties like oncology, cardiology, and psychiatry, with case studies like the GUIDED and PRIME Care trials demonstrating improved drug selection, though challenges remain in achieving significant remission rates. Implementation faces obstacles, including complex genetic variants, limited evidence for multi-gene interactions, and low genomic literacy among clinicians. Despite these challenges, pharmacogenomics is a cornerstone of precision medicine, promising safer and more effective therapies through genetic-guided interventions.

Keywords: *Pharmacogenomics, Pharmacogenetics, Personalized Medicine, Genetic Variations, Drug Metabolism, Cytochrome P450, CYP2D6, CYP2C9, CYP2C19, Adverse Drug Reactions, Precision Medicine*.

How to Cite: Surya Nath Pandey, Mithul V Mammen, Upendra Kumar, Abhishek Anand, Amit Kumar, Abhishek Suma, Tanu shree Vyas., (2025) Genetic Insights: The Power of Pharmacogenomics in Shaping Personalized Treatment Strategies, *Journal of Carcinogenesis*, *Vol.24, No.6s,* 17-24.

1. INTRODUCTION

Pharmacogenomics examines how an individual's genetic makeup influences their response to medications, merging the disciplines of pharmacology and genomics, as derived from the terms themselves [1]. This field promises tailored medications customized to a person's unique genetic profile. While factors such as environment, diet, age, lifestyle, and health status can affect drug responses, understanding a person's genetic composition is considered crucial for developing personalized medications that are both more effective and safer [1]. Drug response, encompassing both therapeutic benefits and adverse reactions, is a complex trait governed by multiple genes. The challenge for scientists lies in identifying all genes involved in drug response to create genetic analyses capable of predicting an individual's reaction to specific

treatments [2].

1.1. Origin of the Concept

The idea of personalized medical care has ancient roots, with practices like the Indian system of selecting herbs and meditation techniques based on individual traits [3]. The history of pharmacogenetics, a precursor to pharmacogenomics, traces back to 510 BC, when Pythagoras noted that some individuals experienced potentially lethal reactions to fava beans, later linked to glucose-6-phosphate dehydrogenase (G6PD) deficiency [4,5]. Over time, significant milestones have shaped this field, as summarized in Table 1, fueling contemporary interest in pharmacogenomics. Variations in the human genome occur approximately every 500–1000 bases [6].

Table 1: A Summary of Pharmacogenomics and Pharmacogenetics Throughout History

Year	Individual(s)	Landmark
510 BC	Pythagoras	Awareness of risks associated with fava bean consumption, later linked to G6PD deficiency [4]
1866	Mendel	Formulation of the genetic code [7]
1906	Garrod	Publication of "Inborn Errors of Metabolism" [8]
1932	Snyder	Description of phenylthiourea nontaster as an autosomal recessive trait [9]
1956	Carson et al.	Identification of glucose-6-phosphate dehydrogenase defect [10]
1957	Motulsky	Proposed that hereditary metabolic abnormalities explain variations in drug responsiveness [11]
1957	Kalow & Genest	Characteristics of serum cholinesterase deficiency [12]
1957	Vogel	Coined the term "pharmacogenetics" [13]
1960	Price Evans	Assessment of acetylator polymorphism characteristics [14]
1962	Kalow	Publication of "Pharmacogenetics - Heredity and the Response to Drugs" [15]
1977/79	Mahgoub et al., Eichelbaum et al.	Discovery of sparteine oxidase and debrisoquine hydroxylase polymorphism [16,17]
1988	Gonzalez et al.	Description of debrisoquine hydroxylase genetic deficiency (CYP2D6) [18]
1988–2000	Various	Identification of variations in phase I and II drug-metabolizing enzymes and drug transporters
2000	Public-private partnership	Completion of the human genome's first draft [19,20]
2000	International SNP Map Working Group	Mapping of 1.42 million SNPs reflecting human genome sequence variation [4]

Pharmacogenetics emerged from Sir Archibald Garrod's early 20th-century proposal on inherent metabolic defects and their role in disease susceptibility [21].

1.2. Development of Pharmacogenetics

In 1957, Friedrich Vogel coined the term "pharmacogenetics" to describe the study of how inherited genetic variations influence drug response [13]. Over subsequent decades, researchers identified key genetic variants affecting drug metabolism, such as acetylator polymorphism and G6PD deficiency. Major breakthroughs in the 1970s and 1980s included the discovery of the CYP2D6 gene's genetic deficiency and the debrisoquine/sparteine polymorphism, paving the way for identifying specific genetic variations in drug-metabolizing enzymes and transporters.

1.3. Importance of Pharmacogenomics in Improving Drug Efficacy and Safety

Pharmacogenomics is vital for optimizing medication therapy by leveraging genetic data to maximize therapeutic benefits and minimize adverse drug reactions (ADRs). Genetic polymorphisms in enzymes and transporters involved in drug metabolism can alter pharmacokinetics, leading to variations in drug tolerance, safety, and efficacy [22]. By analyzing a patient's genetic profile, clinicians can select the appropriate medication and dosage, reducing the risk of ADRs, which are a significant public health concern due to their association with increased morbidity, mortality, and healthcare costs [23]. Studies suggest that preemptive pharmacogenomic testing can reduce ADR incidence by up to 33% [23].

Pharmacogenomics enhances drug efficacy by tailoring medication selection and dosing to an individual's genetic makeup, increasing the likelihood of achieving therapeutic goals, particularly for drugs with complex pharmacokinetics or narrow therapeutic indices [24]. As a cornerstone of precision medicine, pharmacogenomics enables clinicians to move beyond a "one-size-fits-all" approach, delivering personalized, effective, and safer interventions [25]. Additionally,

pharmacogenomics informs drug development by identifying genetic markers associated with drug response, aiding in patient stratification for clinical trials and facilitating the development of targeted therapies [26].

2. BASIC CONCEPTS OF PHARMACOGENOMICS

Genetic diversity significantly influences drug metabolism, impacting the efficacy and safety of pharmaceutical therapies. Understanding these variations is essential for advancing personalized medicine, where treatments are tailored to an individual's genetic profile.

2.1. Pharmacogenetics and Pharmacogenomics

Pharmacogenetics focuses on how genetic variants affect individual drug responses, particularly through drug-metabolizing enzymes, primarily from the cytochrome P450 (CYP) family, which metabolize approximately 80% of prescription drugs [27,28,29,30]. Variations in these genes result in differing enzyme activities, classifying individuals as poor, intermediate, extensive, or ultra-rapid metabolizers. For instance, ultra-rapid metabolizers may break down drugs too quickly, reducing efficacy, while poor metabolizers may experience increased toxicity due to inefficient drug processing [27,28,29,30]. Pharmacogenomics expands this concept to encompass the entire genome, providing a comprehensive understanding of genetic factors influencing drug response and enabling the identification of biomarkers for predicting therapeutic failures and adverse reactions [31].

2.2. Effect on Drug Safety and Effectiveness

2.2.1. Interindividual Variability

Genetic variations in drug-metabolizing enzymes account for 20% to 95% of variability in drug response. For example, variations in the CYP2D6 gene significantly affect the metabolism of antidepressants and cancer drugs like tamoxifen [32].

2.2.2. Ethnic Differences

The frequency of genetic variants varies across ethnic groups, influencing drug metabolism and response. Studies show that CYP450 enzyme variations differ among European, Asian, and African populations, necessitating tailored therapeutic approaches for diverse demographics [33].

2.2.3. Adverse Drug Reactions (ADRs)

Genetic differences can lead to unpredictable ADRs. For instance, specific genetic profiles are linked to severe toxicities and hypersensitivity reactions, underscoring the need for genetic screening before prescribing certain medications [23].

2.3. Clinical Implications

Integrating pharmacogenetic evaluations into clinical practice offers several benefits:

1. **Customized Drug Selection**: Tailoring drug choices to a patient's genetic profile enhances efficacy and reduces side effects [34].
2. **Optimized Dosing**: Adjusting doses based on metabolic capacity ensures safe and effective medication use [35].
3. **Improved Drug Development**: Genetic data in clinical trials enhance understanding of drug safety and efficacy across diverse populations, fostering the development of targeted therapies [36].

2.4. Genotype, Phenotype, and Single Nucleotide Polymorphisms (SNPs)

The concepts of genotype and phenotype, introduced by Wilhelm Johannsen in 1909, are foundational to genetics [37]. The genotype refers to an individual's genetic composition, including diploid or haploid allele pairs (e.g., DD, Dd, dd), while the phenotype describes the observable traits resulting from gene expression [38,39]. Single nucleotide polymorphisms (SNPs) are variations at a single nucleotide position (substitution, deletion, or insertion) in the genome, occurring in both coding and noncoding regions. SNP detection methods, ranging from labor-intensive sequencing to automated techniques, identify these polymorphisms for pharmacogenetic applications [40]. In pharmacogenomics, genotypes, phenotypes, and SNPs collectively influence drug metabolism and response, enabling personalized therapies that improve outcomes and reduce adverse effects.

3. GENETIC CAUSES OF INDIVIDUAL VARIABILITY IN DRUG RESPONSE

Individual variability in drug response poses a significant challenge in pharmacotherapy, leading to differences in efficacy and ADRs. Genetic polymorphisms in drug-metabolizing enzymes, particularly those in the cytochrome P450 (CYP) family, are among the most influential factors affecting drug processing and therapeutic outcomes.

3.1. Polymorphisms in Drug-Metabolizing Enzymes

Enzymes like those in the CYP family primarily govern drug metabolism, with genetic variations causing significant inter individual differences.

3.1.1. Cytochrome P450 2D6 (CYP2D6)

The CYP2D6 gene, located on chromosome 22q13.1, is highly polymorphic, with over 100 identified variants, including point mutations, duplications, deletions, and whole-gene deletions [41,42]. These variants categorize individuals as poor (PM), intermediate (IM), extensive (EM), or ultra-rapid (UM) metabolizers, affecting the metabolism of 20%–25% of drugs, including tricyclic antidepressants, β-blockers, antiarrhythmics, and selective serotonin reuptake inhibitors [43,44]. For instance, PMs with two non-functional alleles exhibit reduced metabolism, while UMs with multiple active gene copies metabolize drugs rapidly [46,47,48,49,50]. In the Caucasian population, approximately 5%–10% are PMs, 10%–17% are IMs, 70%–80% are EMs, and 3%–5% are UMs [46].



Figure 1: Distribution of CYP2D6 Phenotypes in the Caucasian Population

(This pie chart illustrates the approximate distribution of CYP2D6 metabolizer phenotypes in the Caucasian population, with percentages displayed for Poor (PM), Intermediate (IM), Extensive (EM), and Ultra-rapid (UM) metabolizers, based on data from [46]).

Table 2: CYP2D6 Phenotypes and Genotypes

Phenotype	Genotype	References
PM	CYP2D6*3–*8, *11, *16, *18–*21, *38, *40, *42, *44, *56, *62	[46]
EM	CYP2D6*2, *17 x 2, *27, *35, *39, *48	[47]
IM	CYP2D6*10, *14, *17, *18, *36, *41, *47, *49–*51, *54, *55, *57	[48,49]
UM	CYP2D6*2XN (N = 2, 3, 4, 5, or 13)	[46,47]

Note: Classification is based on CYP2D6 enzyme metabolism of probe substrates (bufuralol, debrisoquine, sparteine, dextromethorphan) across studied populations.

3.1.2. Cytochrome P450 2C9 (CYP2C9)

CYP2C9 metabolizes drugs like glipizide, tolbutamide, phenytoin, losartan, and warfarin. The CYP2C9*2 and CYP2C9*3 variants are associated with reduced enzyme activity, decreasing S-warfarin clearance in poor metabolizers and increasing the risk of bleeding, necessitating lower warfarin doses [51,52].

3.1.3. Cytochrome P450 2C19 (CYP2C19)

CYP2C19 metabolizes drugs such as diazepam, citalopram, and proton pump inhibitors like omeprazole. Over 16 variants are linked to varying metabolic activities, with CYP2C19*2 and CYP2C19*3 identifying poor metabolizers, and CYP2C19*17 associated with ultra-rapid metabolizers, prevalent in 18% of Swedes and Ethiopians and 4% of Chinese

populations [53]. Poor metabolizers exhibit higher omeprazole plasma levels, improving acid suppression, while ultra-rapid metabolizers may experience treatment failure due to lower drug levels [53,54].

4. CLINICAL APPLICATIONS OF PHARMACOGENOMICS

Pharmacogenomics is increasingly recognized for its role in enhancing drug efficacy, reducing ADRs, and personalizing medical care. By studying how genetic variations influence drug response, pharmacogenomic testing enables tailored treatment regimens, addressing variability that leads to ineffective treatments or ADRs, which are influenced by genetic factors in 20% to 95% of cases [55,56,57].

4.1. Applications in Medical Specialties

1. **Drug Selection and Dosing**: Pharmacogenomic testing guides the selection and dosing of drugs like beta-blockers and antidepressants based on CYP2D6 variations [58].
2. **ADR Prevention**: Testing identifies individuals at risk of severe ADRs, such as abacavir hypersensitivity linked to HLA-B*5701 [59].
3. **Oncology**: Pharmacogenomics tailors cancer treatments based on tumor genetic mutations [60].
4. **Cardiovascular Medicine**: VKORC1 and CYP2C9 variants guide warfarin dosing to minimize bleeding risks [61].
5. **Psychiatry**: Genetic profiles inform psychotropic drug selection for conditions like depression and anxiety [62].

4.2. Case Studies

4.2.1. Antidepressants

- **GUIDED Trial**: Involving 1,541 patients with major depressive disorder, this trial compared pharmacogenomic-guided therapy with standard care. Guided therapy reduced prescriptions of drugs with drug-gene interactions, with minor improvements (5%–6%) in secondary outcomes, suggesting benefits for patients with significant drug-gene interactions [63].
- **PRIME Care Trial**: This trial assessed pharmacogenomic testing in clinical practice, finding reduced prescriptions of drugs with predicted interactions but no significant improvement in remission rates over 24 weeks [64].

4.2.2. Anticoagulants

- **Warfarin Dosing**: VKORC1 and CYP2C9 variants influence warfarin dosing, with pharmacogenomic-guided dosing achieving therapeutic INR values faster and more reliably [65,66].
- **Clopidogrel Response**: CYP2C19 variants affect clopidogrel metabolism, with poor metabolizers potentially requiring higher doses or alternative drugs to ensure effective antiplatelet therapy [67,68].

5. CHALLENGES IN IMPLEMENTING PHARMACOGENOMICS

Despite its potential, pharmacogenomics faces several obstacles to widespread clinical adoption, categorized as scientific, structural, and educational challenges.

5.1. Genetic Variant Complexity

Pharmacogenes like CYP2D6 exhibit complex architectures, with over 100 variants, including SNPs, copy number variations, and gene rearrangements, complicating test interpretation and clinical application [69].

5.2. Insufficient Evidence for Multi-Gene Interactions

Current guidelines primarily address single-gene interactions, lacking robust data on multi-gene effects, which may not fully capture the complexity of drug metabolism and response [70].

5.3. Dynamic Nature of Genetic Research

The rapid evolution of pharmacogenomics, with frequent discoveries of new variants, challenges the integration of the latest findings into clinical practice [71].

5.4. Limited Genomic Literacy Among Healthcare Professionals

Many clinicians lack sufficient training in pharmacogenomics, reducing confidence in interpreting and applying genetic test results [72].

5.5. Integration into Healthcare Systems

Incorporating pharmacogenomic testing into healthcare workflows requires significant procedural changes, often facing

resistance or funding constraints [73].

5.6. Data Management and Interpretation

Effective integration of genetic data into electronic health records (EHRs) remains underdeveloped, hindering seamless access and interpretation of pharmacogenomic information [74].

REFERENCES

[1] T P A, M SS, Jose A, Chandran L, Zachariah SM. Pharmacogenomics: the right drug to the right person. *J Clin Med Res*. 2009 Oct;1(4):191-4. doi: 10.4021/jocmr2009.08.1255. PMID: 22461867; PMCID: PMC3299179.

[2] Fiers W, Contreras R, Duerinck F, et al. Complete nucleotide sequence of bacteriophage MS2 RNA: primary and secondary structure of the replicase gene. *Nature*. 1976;260(5551):500–507.

[3] Visvikis-Siest S, Theodoridou D, Kontoe M-S, et al. Milestones in Personalized Medicine: From the Ancient Time to Nowadays—the Provocation of COVID-19. *Front Genet*. 2020;11:569175. doi:10.3389/fgene.2020.569175.

[4] Nebert DW. Pharmacogenetics and pharmacogenomics: why is this relevant to the clinical geneticist? *Clin Genet*. 1999;56:345–347.

[5] Pirmohamed M. Pharmacogenetics and pharmacogenomics. *Br J Clin Pharmacol*. 2001 Oct;52(4):345-7. doi: 10.1046/j.0306-5251.2001.01498.x. PMID: 11678777; PMCID: PMC2014592.

[6] Roses AD. Pharmacogenetics and the practice of medicine. *Nature*. 2000;405:857–865. doi:10.1038/35015728.

[7] Mendel JG. Verusche uber Pflanzen-Hybride. *Verhandlungen des naturforschenden Vereines in Brunn*. 1866;4.

[8] Garrod AE. *Inborn Errors of Metabolism*. New York: Oxford University Press.

[9] Snyder LH. Studies in human inheritance IX. The inheritance of taste deficiency in man. *Ohio J Sci*. 1932;32:436–468.

[10] Carson PE, Flanagan CL, Ickes CE, Alvong AS. Enzymatic deficiency in primaquine sensitive erythrocytes. *Science*. 1956;124:484–485.

[11] Motulsky AG. Drug reactions, enzymes and biochemical genetics. *JAMA*. 1957;165:835–837.

[12] Kalow W, Genest K. A method for the detection of atypical forms of human serum cholinesterase. Determination of dibucaine numbers. *Can J Biochem Physiol*. 1957;35:339–346.

[13] Vogel F. Moderne probleme der Humangenetik. *Ergeb Inn Med Kinderheild*. 1959;12:52–125.

[14] Price Evans DAP, Manley KA, McKusick VA. Genetic control of isoniazid metabolism in man. *Br Med J*. 1960;2:4484–4491.

[15] Kalow W. *Pharmacogenetics – Heredity and the Responses to Drugs*. Philadelphia: W.B. Saunders.

[16] Mahgoub A, Idle JR, Dring LG, Lancaster R, Smith RL. Polymorphic hydroxylation of debrisoquine in man. *Lancet*. 1977;ii:584–586.

[17] Eichelbaum M, Spannbrucker N, Steincke B, Dengler HJ. Defective N-oxidation of sparteine in man, a new pharmacogenetic defect. *Eur J Clin Pharmacol*. 1979;16:183–187.

[18] Gonzalez FJ, Skoda RC, Kimura S, et al. Characterization of the common genetic-defect in humans deficient in debrisoquine metabolism. *Nature*. 1988;331:442–446.

[19] Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. *Nature*. 2001;409(6822):860–921. doi:10.1038/35057062.

[20] Venter JC, Adams MD, Myers EW, et al. The sequence of the human genome. *Science*. 2001;291:1304. doi:10.1126/science.1058040.

[21] [Reference not provided in original text; placeholder for Garrod's work].

[22] Principi N, Petropulacos K, Esposito S. Impact of Pharmacogenomics in Clinical Practice. *Pharmaceuticals (Basel)*. 2023 Nov 13;16(11):1596. doi: 10.3390/ph16111596. PMID: 38004461; PMCID: PMC10675377.

[23] Chenchula S, Atal S, Uppugunduri CRS. A review of real-world evidence on preemptive pharmacogenomic testing for preventing adverse drug reactions: a reality for future health care. *Pharmacogenomics J*. 2024;24:9. doi:10.1038/s41397-024-00326-1.

[24] Daly AK. Pharmacogenetics: a general review on progress to date. *Br Med Bull*. 2017;124(1):65–79. doi:10.1093/bmb/ldx035.

[25] Li D, Xie AH, Liu Z, et al. Linking Pharmacogenomic Information on Drug Safety and Efficacy with Ethnic Minority Populations. *Pharmaceutics*. 2020 Oct 25;12(11):1021. doi: 10.3390/pharmaceutics12111021. PMID: 33113799; PMCID: PMC7693750.

[26] Qahwaji R, Ashankyty I, Sannan NS, et al. Pharmacogenomics: A Genetic Approach to Drug Development and Therapy. *Pharmaceuticals*. 2024;17(7):940. doi:10.3390/ph17070940.

[27] Pinto N, Dolan ME. Clinically relevant genetic variations in drug metabolizing enzymes. *Curr Drug Metab*. 2011 Jun;12(5):487-97. doi: 10.2174/138920011795495321. PMID: 21453273; PMCID: PMC3110519.

[28] Zhou S-F. Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. *Clin Pharmacokinet*. 2009;48:689-723.

[29] McDonnell AM, et al. Basic review of the cytochrome p450 system. *J Adv Pract Oncol*. 2013;4:263-268.

[30] Goodman LS, Gilman A, Brunton LL, et al. *Goodman & Gilman's the pharmacological basis of therapeutics*. 11th ed. McGraw-Hill; 2006.
[31] Ahmed S, Zhou Z, Zhou J, Chen SQ. Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine. *Genomics Proteomics Bioinformatics*. 2016 Oct;14(5):298-313. doi: 10.1016/j.gpb.2016.03.008. PMID: 27729266; PMCID: PMC5093856.
[32] Belle DJ, Singh H. Genetic factors in drug metabolism. *Am Fam Physician*. 2008 Jun 1;77(11):1553-60. PMID: 18581835.
[33] Afsar NA, Bruckmueller H, Werk AN, et al. Implications of genetic variation of common Drug Metabolizing Enzymes and ABC Transporters among the Pakistani Population. *Sci Rep*. 2019;9:7323. doi:10.1038/s41598-019-43736-z.
[34] Schärfe CPI, Tremmel R, Schwab M, et al. Genetic variation in human drug-related genes. *Genome Med*. 2017;9:117. doi:10.1186/s13073-017-0502-5.
[35] Ingelman-Sundberg M, Mkrtchian S, Zhou Y, Lauschke VM. Integrating rare genetic variants into pharmacogenetic drug response predictions. *Human Genomics*. 2018;12(1):26. doi:10.1186/s40246-018-0157-3.
[36] Stingl J, Brockmöller J, Viviani R. Genetic variability of drug-metabolizing enzymes: the dual impact on psychiatric therapy and regulation of brain function. *Mol Psychiatry*. 2013;18:273–287. doi:10.1038/mp.2012.42.
[37] Lewontin RC. Genotype and phenotype. In: *Keywords in Evolutionary Biology*. Keller EF, Lloyd E, eds. Cambridge, MA: Harvard University Press; 1992:137–144.
[38] Klug WS, Cummings MR. *Concepts of Genetics*. New York: Macmillan; 1991.
[39] Mahner M, Kary M. What Exactly Are Genomes, Genotypes and Phenotypes? And What About Phenomes? *J Theor Biol*. 1997;186(1):55–63. doi:10.1006/jtbi.1996.0335.
[40] Kwok PY, Chen X. Detection of single nucleotide polymorphisms. *Curr Issues Mol Biol*. 2003 Apr;5(2):43-60. PMID: 12793528.
[41] Gough AC, Smith CA, Howell SM, et al. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction, in situ hybridization, and linkage analysis. *Genomics*. 1993;15:430–432.
[42] Kimura S, Umeno M, Skoda RC, et al. The human debrisoquine 4-hydroxylase (CYP2D) locus: sequence and identification of the polymorphic CYP2D6 gene, a related gene, and a pseudogene. *Am J Hum Genet*. 1989;45:889–904.
[43] Zhou SF, Di YM, Chan E, et al. Clinical pharmacogenetics and potential application in personalized medicine. *Curr Drug Metab*. 2008;9:738–784.
[44] Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. *Pharmacogenomics J*. 2005;5:6–13.
[45] Kirchheiner J, Nickchen K, Bauer M, et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. *Mol Psychiatry*. 2004;9:442–473.
[46] Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. *Naunyn Schmiedebergs Arch Pharmacol*. 2004;369:23–37.
[47] Marez D, Legrand M, Sabbagh N, et al. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. *Pharmacogenetics*. 1997;7:193–202.
[48] Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. *Pharmacogenomics*. 2002;3:229–243.
[49] Ji L, Pan S, Marti-Jaun J, et al. Single-step assays to analyze CYP2D6 gene polymorphisms in Asians: allele frequencies and a novel *14B allele in mainland Chinese. *Clin Chem*. 2002;48:983–988.
[50] Koren G, Cairns J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. *Lancet*. 2006;368:704.
[51] Aquilante CL, Langaee TY, Lopez LM, et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements. *Clin Pharmacol Ther*. 2006;79(4):291-302.
[52] Higashi MK, Veenstra DL, Kondo LM, et al. Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. *JAMA*. 2002;287(13):1690-1698.
[53] Sim SC, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. *Clin Pharmacol Ther*. 2006;79(1):103-113.
[54] de Leon J, Dinsmore L, Wedlund P. Adverse drug reactions to oxycodone and hydrocodone in CYP2D6 ultrarapid metabolizers. *J Clin Psychopharmacol*. 2003;23(4):420-421.
[55] Belle DJ, Singh H. Genetic factors in drug metabolism. *Am Fam Physician*. 2008;77(11):1553-1560.
[56] Shukla R. Pharmacogenomics: Overview, Applications, and Recent Developments. In: *Drug Design - Novel Advances in the Omics Field and Applications*. IntechOpen; 2021. doi:10.5772/intechopen.93737.
[57] Adams SM, Crisamore KR, Empey PE. Clinical Pharmacogenomics: Applications in Nephrology. *Clin J Am Soc Nephrol*. 2018 Oct 8;13(10):1561-1571. doi: 10.2215/CJN.02730218. PMID: 29793969; PMCID: PMC6218819.

[58] Van Der Wouden CH, Bohringer S, Cecchin E, et al. Generating evidence for precision medicine: Considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study. *Pharmacogenet Genom*. 2020. doi: 10.1097/FPC.0000000000000405.
[59] Relling MV, Klein TE, Gammal RS, et al. The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later. *Clin Pharmacol Ther*. 2019;107:171–175. doi: 10.1002/cpt.1651.
[60] Cecchin E, Stocco G. Pharmacogenomics and Personalized Medicine. *Genes (Basel)*. 2020 Jun 22;11(6):679. doi: 10.3390/genes11060679. PMID: 32580376; PMCID: PMC7348959.
[61] Adams SM, Crisamore KR, Empey PE. Clinical Pharmacogenomics: Applications in Nephrology. *Clin J Am Soc Nephrol*. 2018;13(10):1561-1571. doi: 10.2215/CJN.02730218.
[62] Hippman C, Nislow C. Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. *J Pers Med*. 2019 Aug 7;9(3):40. doi: 10.3390/jpm9030040. PMID: 31394823; PMCID: PMC6789586.
[63] Stingl J, Viviani R. Polymorphism in CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. *J Intern Med*. 2015;277(2):167-177. doi:10.1111/joim.12317.
[64] Oslin DW, Lynch KG, Shih M, et al. Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. *JAMA*. 2022;328(2):151–161. doi:10.1001/jama.2022.9805.
[65] Weinshilboum RM, Wang L. Pharmacogenomics: Precision Medicine and Drug Response. *Mayo Clin Proc*. 2017 Nov;92(11):1711-1722. doi: 10.1016/j.mayocp.2017.09.001. PMID: 29101939; PMCID: PMC5682947.
[66] Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. *Pharmacogenetics*. 1998;8(4):283-289.
[67] Plenge RM. Priority index for human genetics and drug discovery. *Nat Genet*. 2019;51:1073–1075.
[68] Jacobs AT, Martinez Castaneda-Cruz D, Rose MM, Connelly. Targeted therapy for breast cancer: an overview of drug classes and outcomes. *Biochem Pharmacol*. 2022;204:115209.
[69] Weinshilboum RM, Wang L. Pharmacogenomics: Precision Medicine and Drug Response. *Mayo Clin Proc*. 2017 Nov;92(11):1711-1722. doi: 10.1016/j.mayocp.2017.09.001. PMID: 29101939; PMCID: PMC5682947.
[70] Hippman C, Nislow C. Pharmacogenomic Testing: Clinical Evidence and Implementation Challenges. *J Pers Med*. 2019 Aug 7;9(3):40. doi: 10.3390/jpm9030040. PMID: 31394823; PMCID: PMC6789586.
[71] Cecchin E, Stocco G. Pharmacogenomics and Personalized Medicine. *Genes (Basel)*. 2020 Jun 22;11(6):679. doi: 10.3390/genes11060679. PMID: 32580376; PMCID: PMC7348959.
[72] Khanna D, Fitzgerald JD, Khanna PP, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. *Arthritis Care Res (Hoboken)*. 2012;64:1431–1446. doi: 10.1002/acr.21772.
[73] Arbitrio M. Pharmacogenomics: Challenges and Future. *Genes*. 2024;15(6):714. doi:10.3390/genes15060714.
[74] Tai HL, Krynetski EY, Yates CR, et al. Thiopurine S-methyltransferase deficiency: two nucleotide transitions define the most prevalent mutant allele associated with loss of catalytic activity in Caucasians. *Am J Hum Genet*. 1996 Apr;58(4):694–702.